The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF
- PMID: 1824777
The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF
Abstract
Using a dimethylbenzanthracene-induced immunogenic nonmetastatic murine mammary adenocarcinoma in BALB/c mice, our previous work has shown that splenocytes from tumor bearers have reduced responses to both mitogens and Ag including tumor-associated Ag. NK and cytotoxic T cell activities are also reduced in splenocytes of tumor bearers. Mac-1+2+ macrophages induced in mammary tumor bearers are capable of down-regulating lymphocyte responses to mitogens and tumor-associated Ag by cell to cell contact interaction and increased PGE2 production. We have found that the tumor constitutively releases a granulocyte-macrophage (GM)-CSF-like factor in vivo and in vitro, which may be responsible for the systemic increase in cells of the macrophage lineage in tumor-bearing mice. A tumor cell line established from the in vivo tumor expresses and releases GM-CSF as shown by Northern and Western blot analyses. Daily i.p. injections for 3 wk of 10,000 U of rGM-CSF into normal mice induces hemopoietic and immunologic alterations similar to those observed in tumor bearers. Mac-1+ and/or Mac-2+ macrophages can also be detected in the spleens and bone marrow of the mice treated with rGM-CSF. Additionally, splenocytes from rGM-CSF-treated mice have reduced responses to mitogens and their peritoneal exudate cells can cause in vitro down-regulation of proliferative responses of lymphocytes from normal mice. The suppression can be partially reversed by the addition of indomethacin to the cultures suggesting that PGE2 may contribute to the effect. rGM-CSF enhances the in vitro release of PGE2 by the spleen, bone marrow, and peritoneal cells of normal mice. These data indicate that the high levels of GM-CSF constitutively produced by the tumor may be responsible for the hemopoietic changes and immunologic alterations observed in tumor-bearing mice.
Similar articles
-
Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor.Cancer Res. 1990 Jan 15;50(2):227-34. Cancer Res. 1990. PMID: 2136804
-
Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor.J Immunol. 1991 Oct 15;147(8):2816-23. J Immunol. 1991. PMID: 1918995
-
Epidermal Langerhans cells from mice bearing a granulocyte macrophage-colony stimulating factor-producing mammary tumor display impaired accessory functions.Anticancer Res. 1996 Jan-Feb;16(1):9-16. Anticancer Res. 1996. PMID: 8615675
-
Immunomodulatory action of eicosanoids and other small molecular weight products of macrophages.Ann Ist Super Sanita. 1991;27(1):67-9. Ann Ist Super Sanita. 1991. PMID: 1683527 Review.
-
Modulation of the immune system by mammary tumor-derived factors.Cancer Invest. 1991;9(6):643-53. doi: 10.3109/07357909109039876. Cancer Invest. 1991. PMID: 1684133 Review. No abstract available.
Cited by
-
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.Blood. 2000 Dec 1;96(12):3838-46. Blood. 2000. PMID: 11090068 Free PMC article.
-
Eicosanoids and the immunology of cancer.Cancer Metastasis Rev. 1994 Dec;13(3-4):337-48. doi: 10.1007/BF00666103. Cancer Metastasis Rev. 1994. PMID: 7712595 Review.
-
Orosomucoid 1 drives opportunistic infections through the polarization of monocytes to the M2b phenotype.Cytokine. 2015 May;73(1):8-15. doi: 10.1016/j.cyto.2015.01.017. Epub 2015 Feb 14. Cytokine. 2015. PMID: 25689617 Free PMC article.
-
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.J Immunol. 2014 Feb 1;192(3):1286-93. doi: 10.4049/jimmunol.1202498. Epub 2013 Dec 23. J Immunol. 2014. PMID: 24367029 Free PMC article.
-
Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts.Jpn J Cancer Res. 1994 Nov;85(11):1137-43. doi: 10.1111/j.1349-7006.1994.tb02919.x. Jpn J Cancer Res. 1994. PMID: 7829399 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials